Price History:17.68%(TTM)
Over the latest trailing 12-month period, price cagr is +17.68%. The comparable SPY value is +19.16%. Year-to-date price return is +6.39%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$90.78
+$1.06 (+1.18%)
Previous Close: $89.72
Last Session
- Open
- $90.31
- Day High
- $92.46
- Day Low
- $89.33
- Volume
- 14.42M
- Avg Volume
- 5.09M
52-Week Position
92%
of the 52-week price range
- From 52-week high
- -1.82%
- From 52-week low
- +25.56%
52-Week Price Range
52-Week Low
$72.30
Oct 16, 2025
Current Price
$90.78
92% of range
52-Week High
$92.46
Jun 26, 2026
Price Returns by Period
1 Day
+1.18%
7 Days
+3.91%
30 Days
+4.98%
YTD
+6.39%
1 Year
+16.07%
vs 52W High
-1.82%
EW Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+0.48%
Price CAGR (5Y)
-2.60%
Total Return CAGR (3Y)
+0.48%
Total Return CAGR (5Y)
-2.60%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $90.78 |
| Previous Close | $89.72 |
| Day Range | $89.33 - $92.46 |
| 52-Week Range | $72.30 - $92.46 |
| Volume | 14.42M |
| Average Volume | 5.09M |
| Market Cap | $52.27B |
| % from 52W High | -1.82% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian